Characteristics of unpublished registered studies: protein subunit (91 studies)
Registration number	Registration date	Status	Design	Interventions	Estimated sample size	Phase
NCT04453852	1 July 2020	Completed	Parallel	COVAX‐19	40	Phase 1
IRCT20201214049709N1	21 January 2021	Completed	Parallel	RAZI‐COV PARS	133	Phase 1
RPCEC00000345	26 November 2020	Not recruiting	Parallel	CIGB‐669 (RBD/AgnHB)	88	Phase 1/Phase 2
RPCEC00000381	1 July 2021	Not recruiting	Parallel	CIGB‐66 (RBD/aluminium hydroxide)	592	Phase 1/Phase 2
RPCEC00000382	9 July 2021	Not recruiting	Parallel	CIGB‐669 (RBD/HBcAg)	120	Phase 1/Phase 2
NCT05084989	20 October 2021	Not recruiting	Cross‐over	Recov – recombinant 2‐component COVID‐19 vaccine (cho cell)	20,301	Phase 2/Phase 3
RPCEC00000346	26 November 2020	Not recruiting	Factorial	CIGB‐66 (RBD/aluminium hydroxide)	132	Phase 1/Phase 2
PACTR202107562417077	23 July 2021	Not recruiting	Factorial	Recombinant SARS‐CoV‐2 fusion protein vaccine (v‐01)	22,500	Phase 3
PACTR202108616900606	6 August 2021	Not recruiting	Factorial	CpG 1018/alum adjuvant + scb‐2019	600	Phase 3
ACTRN12620001308987	4 December 2020	Not recruiting	Parallel	RBD + alum adjuvant	255	Phase 1/Phase 2
ACTRN12621000882820	8 July 2021	Not recruiting	Parallel	IVX‐411	84	Phase 2
ChiCTR2000035691	16 August 2020	Not recruiting	Parallel	Recombinant SARS‐CoV‐2 vaccine (CHO Cell)	50	Phase 1
ChiCTR2000037518	28 August 2020	Not recruiting	Parallel	Recombinant SARS‐CoV‐2 vaccine (Sf9 Cell)	168	Phase 1
ChiCTR2000040153	22 November 2020	Not recruiting	Parallel	Recombinant SARS‐CoV‐2 vaccine (CHO Cell)	29,000	Phase 3
ChiCTR2100048439	7 July 2021	Not recruiting	Parallel	Recombinant SARS‐CoV‐2 vaccine (CHO cell)	75	Phase 1
CTRI/2020/11/029032	10 November 2020	Not recruiting	Parallel	BECOV2	360	Phase 1/Phase 2
CTRI/2021/02/031554	25 February 2021	Not recruiting	Parallel	SARS‐CoV‐2 rS/Matrix M1‐adjuvant	1600	Phase 2/Phase 3
JPRN‐jRCT2051200092	9 December 2020	Not recruiting	Parallel	S‐268019	300	Phase 1/Phase 2
NCT04473690	16 July 2020	Not recruiting	Parallel	KBP‐COVID‐19	180	Phase 1/Phase 2
NCT04672395	17 December 2020	Not recruiting	Parallel	SCB‐2019 + CpG 1018/Alum‐adjuvant	22,000	Phase 2/Phase 3
NCT04683224	24 December 2020	Not recruiting	Parallel	UB‐612	7320	Phase 2/Phase 3
NCT04712110	15 January 2021	Not recruiting	Parallel	TAK‐019	200	Phase 1/Phase 2
NCT04742738	8 February 2021	Not recruiting	Parallel	GBP510 + aluminium hydroxide adjuvant	260	Phase 1/Phase 2
NCT04750343	11 February 2021	Not recruiting	Parallel	GBP510 + AS03 adjuvant	320	Phase 1/Phase 2
NCT04760743	18 February 2021	Not recruiting	Parallel	NBP2001	50	Phase 1
NCT04780035	3 March 2021	Not recruiting	Parallel	EpiVacCorona	3000	Phase 3
NCT04784767	5 March 2021	Not recruiting	Parallel	SpFN_1B‐06‐PL + ALFQ (QS21 adjuvant)	72	Phase 1
NCT04887207	14 May 2021	Not recruiting	Parallel	Recombinant SARS‐CoV‐2 vaccine (Sf9 Cell)	40,000	Phase 3
NCT04930003	18 June 2021	Not recruiting	Parallel	QazCoVac‐P	244	Phase 1/Phase 2
NCT04944368	29 June 2021	Not recruiting	Parallel	SARS‐CoV‐2 recombinant spike protein + Advax‐SM adjuvant	400	Phase 2
NCT04950751	6 July 2021	Not recruiting	Parallel	SCB‐2020S	150	Phase 2
NCT04951388	6 July 2021	Not recruiting	Parallel	COV1901	385	Phase 2
NCT04954131	8 July 2021	Not recruiting	Parallel	SCB‐2019	800	Phase 2
PACTR202011523101903	2 November 2020	Not recruiting	Parallel	SARS‐CoV‐2 recombinant protein vaccine + AS03 adjuvant	34,520	Not reported
PACTR202103845381761	3 March 2021	Not recruiting	Parallel	Recombinant SARS‐CoV‐2 vaccine (Sf9 Cell)	40,000	Phase 3
RPCEC00000347	17 December 2020	Not recruiting	Parallel	FINLAY‐FR‐2 anti‐SARS‐CoV‐2 vaccine	910	Phase 2
RPCEC00000359	18 March 2021	Not recruiting	Parallel	CIGB‐66 (RBD/aluminium hydroxide)	48,000	Phase 3
RPCEC00000366	9 April 2021	Not recruiting	Parallel	FINLAY‐FR‐1A anti‐SARS‐CoV‐2 Vaccine	450	Phase 2
NCT05007509	16 August 2021	Not recruiting	Parallel	Hipra	30	Phase 1/Phase 2
NCT05005559	13 August 2021	Not recruiting	Parallel	SARS‐CoV‐2 recombinant spike p + Advax‐cpg adjuvant	16,876	Phase 3
NCT05012787	19 August 2021	Not recruiting	Parallel	SCB‐2019 + CpG 1018 adjuvant	300	Phase 3
NCT05013983	20 August 2021	Not recruiting	Parallel	Recombinant SARS‐CoV‐2 vaccine (Sf9 Cell)	600	Phase 1/Phase 2
NCT05016934	23 August 2021	Not recruiting	Parallel	Versamune‐CoV‐2FC	360	Phase 1/Phase 2
JPRN‐jRCT2051210057	29 July 2021	Not recruiting	Parallel	Recombinant SARS‐CoV‐2 vaccine (Sf9 Cell)	240	Phase 1/Phase 2
NCT05029856	1 September 2021	Not recruiting	Parallel	Monovalent B.1.351 vaccine + Matrix‐M1 Adjuvant	240	Phase 1/Phase 2
CTRI/2021/08/036074	31 August 2021	Not recruiting	Parallel	Corbevax	2140	Phase 3
NCT05043285	14 September 2021	Not recruiting	Parallel	SCTV01C	8420	Phase 2/Phase 3
NCT05043311	14 September 2021	Not recruiting	Parallel	SCTV01C	12,420	Phase 2/Phase 3
NCT05067894	5 October 2021	Not recruiting	Parallel	SARS‐CoV‐2 recombinant protein vaccine	780	Phase 1/Phase 2
JPRN‐jRCT2031210269	23 August 2021	Not recruiting	Parallel	S‐268019	60	Phase 1/Phase 2
RPCEC00000385	23 July 2021	Not recruiting	Parallel	Finlay‐fr‐1a anti‐SARS‐CoV‐2 vaccine + FINLAY‐Fr‐1 anti‐SARS‐CoV‐2 vaccine	1166	Phase 2
NCT05096832	27 October 2021	Not recruiting	Parallel	Recombinant SARS‐CoV‐2 fusion protein vaccine (v‐01)	10,722	Phase 3
NCT04961541	14 July 2021	Not recruiting	Parallel	ICC vaccine	720	Phase 1/Phase 2
NCT05087368	21 October 2021	Not recruiting	Parallel	Alum adjuvant + SCB‐2019	520	Phase 2
NCT04522089	21 August 2020	Not recruiting	Sequential assignment	AdimrSC‐2f	70	Phase 1
NCT04550351	16 September 2020	Not recruiting	Sequential assignment	Recombinant SARS‐CoV‐2 vaccine (CHO cell)	50	Phase 1/Phase 2
RPCEC00000360	19 March 2021	Not recruiting	Single‐group assignment	FINLAY‐FR‐2 anti‐SARS‐CoV‐2 vaccine + FINLAY‐FR‐1A anti‐SARS‐CoV‐2 vaccine	150,000	Not reported
RPCEC00000363	27 March 2021	Not recruiting	Single group assignment	CIGB‐66 (RBD/aluminium hydroxide)	124,000	Not reported
IRCT20150303021315N23	24 May 2021	Ongoing	Parallel	SARS‐CoV‐2 spike (S) protein subunit vaccine + Advax‐CpG adjuvant	400	Phase 2
IRCT20201214049709N2	13 April 2021	Ongoing	Parallel	RAZI‐COV PARS	500	Phase 2
IRCT20150303021315N24	3 August 2021	Ongoing	Parallel	SARS‐CoV‐2 recombinant spike protein + Advax‐SM adjuvant	16,876	Phase 3
IRCT20210303050558N1	24 April 2021	Ongoing	Parallel	FINLAY‐FR‐2 anti‐SARS‐CoV‐2 vaccine	24,000	Phase 3
ACTRN12621000738820	11 June 2021	Ongoing	Parallel	IVX‐411	84	Phase 1
ChiCTR2000039994	17 November 2020	Ongoing	Parallel	Recombinant SARS‐CoV‐2 vaccine (Sf9 Cell)	960	Phase 2
ChiCTR2100042374	21 January 2021	Ongoing	Parallel	Recombinant SARS‐CoV‐2 vaccine (Sf9 Cell)	4800	Phase 2
EUCTR2020‐004272‐17‐DE	6 January 2021	Ongoing	Parallel	SCB‐2019	800	Phase 2/Phase 3
IRCT20210620051639N1	25 June 2021	Ongoing	Parallel	Noora	70	Phase 1
NCT04636333	19 November 2020	Ongoing	Parallel	Recombinant SARS‐CoV‐2 vaccine (CHO Cell)	216	Phase 1
NCT04646590	30 November 2020	Ongoing	Parallel	Recombinant SARS‐CoV‐2 vaccine (CHO Cell)	29,000	Phase 3
NCT04773067	26 February 2021	Ongoing	Parallel	UB‐612	3850	Phase 2
NCT04783311	5 March 2021	Ongoing	Parallel	EuCorVac‐19	280	Phase 1/Phase 2
NCT04813562	24 March 2021	Ongoing	Parallel	Recombinant SARS‐CoV‐2 vaccine (CHO Cell)	480	Phase 2
NCT04818801	26 March 2021	Ongoing	Parallel	ReCOV – recombinant 2‐component COVID‐19 vaccine (CHO cell)	160	Phase 1
NCT04822025	30 March 2021	Ongoing	Parallel	MVC‐COV1901	400	Phase 2
NCT04869592	3 May 2021	Ongoing	Parallel	Recombinant SARS‐CoV‐2 vaccine (CHO Cell)	3580	Phase 1/Phase 2
NCT04885361	13 May 2021	Ongoing	Parallel	CoVepiT (OSE13E)	48	Phase 1
NCT04904471	27 May 2021	Ongoing	Parallel	Recombinant SARS‐CoV‐2 vaccine (Sf9 Cell)	40,000	Phase 3
NCT04904549	27 May 2021	Ongoing	Parallel	SARS‐CoV‐2 adjuvanted recombinant protein vaccine (monovalent)	37,430	Phase 3
NCT04922788	11 June 2021	Ongoing	Parallel	Nanocovax	13,000	Phase 3
NCT04982068	29 July 2021	Ongoing	Parallel	202‐CoV	144	Phase 1
NCT04990544	4 August 2021	Ongoing	Parallel	202‐CoV	1056	Phase 2
IRCT20201214049709N3	29 August 2021	Ongoing	Parallel	RAZI‐COV PARS	41,128	Phase 3
NCT05069129	6 October 2021	Ongoing	Parallel	Recombinant SARS‐CoV‐2 vaccine (CHO Cell)	1848	Phase 1/Phase 2
NCT05091411	25 October 2021	Ongoing	Parallel	Recombinant SARS‐CoV‐2 vaccine (CHO Cell)	1680	Phase 3
NCT05096845	27 October 2021	Ongoing	Parallel	Recombinant SARS‐CoV‐2 fusion protein vaccine (v‐01)	22,500	Phase 3
NCT05097053	27 October 2021	Ongoing	Parallel	Mvc‐cov1901	200	Phase 4
ChiCTR2100050849	5 September 2021	Ongoing	Parallel	Recombinant SARS‐CoV‐2 vaccine (CHO Cell)	14,600	Phase 3
NCT04702178	8 January 2021	Ongoing	Sequential assignment	COVAC‐2	108	Phase 1/Phase 2
NCT04961359	14 July 2021	Ongoing	Sequential assignment	Recombinant SARS‐CoV‐2 vaccine (CHO cell)	75	Phase 1
NCT04718467	22 January 2021	Cancelled	Parallel	Recombinant SARS‐CoV‐2 vaccine (Sf9 Cell)	0	Phase 2
NCT04806529	19 March 2021	Cancelled	Parallel	Adjuvanted SARS‐CoV‐2 subunit vaccine (aCoV2)	0	Phase 2/Phase 3